Pfizer Inc.

Pfizer Inc.

PFE

Market Cap$126.67B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Pfizer Inc.Pfizer Inc.16.27.63%9%2.3-

Earnings Call Q1 2025

April 29, 2025 - AI Summary

Financial Performance: Pfizer reported first-quarter 2025 revenues of $13.7 billion, a 6% operational decline compared to the same quarter last year. The decline was primarily due to lower revenues from Paxlovid and Medicare Part D design changes. However, adjusted diluted EPS was $0.92, exceeding expectations due to strong gross margin and cost management measures.
Cost Management Initiatives: The company has implemented productivity improvement programs resulting in a 12% operational decrease in adjusted operating expenses to $5.2 billion. Pfizer anticipates $7.7 billion in savings by the end of 2027 through ongoing cost realignment and productivity strategies, which are essential to counteract expected losses from upcoming product patent expirations (LOEs).
Strategic Focus on R&D and Pipeline: Pfizer is enhancing R&D productivity, emphasizing a disciplined approach to advancing its pipeline, particularly in cardiometabolic and oncology programs. The focus includes internal programs and potential partnerships, with expectations of multiple regulatory decisions and Phase 3 study readouts in 2025.

Exclusive for Stockcircle Pro members

Sign upSign Up
$24.00

Target Price by Analysts

3.9% upsidePfizer Target Price DetailsTarget Price
$64.30

Current Fair Value

178.5% upside

Undervalued by 178.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$126.67 Billion
Enterprise Value$126.67 Billion
Dividend Yield$1.7 (7.630161579892281%)
Earnings per Share$1.42
Beta0.5
Outstanding Shares5,705,769,230

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio16.16
PEG-340.15
Price to Sales2.31
Price to Book Ratio1.54
Enterprise Value to Revenue2.03
Enterprise Value to EBIT9.37
Enterprise Value to Net Income16
Total Debt to Enterprise0
Debt to Equity0

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Pfizer Inc.

CEO: Albert Bourla